-transparent.png){kind=logo}
For the patient undergoing percutaneous coronary intervention, the administration of a platelet glycoprotein IIb/IIIa receptor blocker reduces the incidence of a periprocedural nonfatal myocardial infarction and the need for unplanned emergency stenting. In the diabetic patient undergoing intracoronary stenting, the use of a platelet glycoprotein IIb/IIIa receptor blocker appears to decrease the need for subsequent target vessel revascularization. There is considerable evidence in support of the use of glycoprotein IIb/IIIa receptor inhibitors in all categories of patients--"high-risk" patients, "low-risk" patients, and those undergoing primary angioplasty for acute myocardial infarction--and for the full armamentarium of percutaneous procedures (angioplasty, directional atherectomy, rotational atherectomy, and intracoronary stenting).
W R Pitts, and
R A Lange
October 1997,
The New England journal of medicine,
W R Pitts, and
R A Lange
October 1997,
The New England journal of medicine,
W R Pitts, and
R A Lange
April 2000,
Journal of the American College of Cardiology,
W R Pitts, and
R A Lange
May 1998,
The New England journal of medicine,
W R Pitts, and
R A Lange
January 2001,
Current controlled trials in cardiovascular medicine,
W R Pitts, and
R A Lange
December 2002,
Journal of the American College of Cardiology,
W R Pitts, and
R A Lange
January 2000,
Indian heart journal,
W R Pitts, and
R A Lange
February 2001,
American heart journal,
W R Pitts, and
R A Lange
June 1998,
Seminars in interventional cardiology : SIIC,
W R Pitts, and
R A Lange
May 2003,
The American journal of cardiology,
